UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000035622
Receipt number R000040516
Scientific Title A Multicenter Phase II study of Trastuzumab emtansine for non-small cell lung cancer positive for HER2 exon 20 insertion mutation.
Date of disclosure of the study information 2019/01/22
Last modified on 2022/01/24 09:11:42

No. Disposal Last modified on Item of update
1 Insert 2019/01/22 15:52:06
2 Update 2019/02/06 15:25:44 Institutions
3 Update 2019/02/08 11:30:31 Institutions
4 Update 2019/02/28 11:12:25 Recruitment status
5 Update 2019/04/01 14:32:47 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
Institutions
6 Update 2019/05/10 13:57:14 Institutions
7 Update 2019/05/29 10:28:08 Institutions
8 Update 2019/08/22 10:03:41 Date of IRB
Last follow-up date
9 Update 2019/08/22 10:08:23 Institutions
10 Update 2020/01/22 11:13:47 Secondary IDs
Study ID_1
Org. issuing International ID_1
Org. issuing International ID_1
11 Update 2020/04/09 17:48:08 UMIN ID1
12 Update 2020/04/23 16:04:10 Organization
Organization
Division name
Division name
Address
Address
TEL
Email
Email1
Email
13 Update 2020/07/28 11:20:13 Recruitment status
14 Update 2020/07/28 11:21:03 Number of participants that the trial has enrolled
15 Update 2021/07/26 08:49:50 Date of closure to data entry
Date trial data considered complete
Date analysis concluded
16 Update 2022/01/24 09:10:56 Recruitment status
17 Update 2022/01/24 09:11:42 Publication of results
Date of the first journal publication of results